Institution
Eisai
Company•Tokyo, Japan•
About: Eisai is a company organization based out in Tokyo, Japan. It is known for research contribution in the topics: Lenvatinib & Alkyl. The organization has 4441 authors who have published 5182 publications receiving 134654 citations. The organization is also known as: Myoan Eisai.
Topics: Lenvatinib, Alkyl, Eribulin, Population, Donepezil
Papers published on a yearly basis
Papers
More filters
••
Kindai University1, University of California, Los Angeles2, Yonsei University3, University of Bologna4, California Pacific Medical Center5, Fourth Military Medical University6, Gdańsk Medical University7, University of Bordeaux8, Hannover Medical School9, Beatson West of Scotland Cancer Centre10, Eisai11, National Taiwan University12
TL;DR: Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma and the safety and tolerability profiles of lenvatinIB were consistent with those previously observed.
3,046 citations
••
TL;DR: It is reported that PAI values obtained at different concentrations of serum albumin show a linear relationship with the logarithm of protein concentration in LC-MS/MS experiments, and the values of emPAI are suggested that they should be reported in large scale proteomic identification projects.
1,989 citations
••
TL;DR: It is demonstrated that TLR4 is involved in lipopolysaccharide signaling and serves as a cell-surface co-receptor for CD14, leading to lipopoly Saccharide-mediated NF-κB activation and subsequent cellular events.
1,874 citations
••
TL;DR: MassBank is the first public repository of mass spectra of small chemical compounds for life sciences and provides a merged spectrum for each compound prepared by merging the analyzed ESI-MS(2) data on an identical compound under different collision-induced dissociation conditions.
Abstract: MassBank is the first public repository of mass spectra of small chemical compounds for life sciences (<3000 Da). The database contains 605 electron-ionization mass spectrometry (EI-MS), 137 fast atom bombardment MS and 9276 electrospray ionization (ESI)-MS(n) data of 2337 authentic compounds of metabolites, 11 545 EI-MS and 834 other-MS data of 10,286 volatile natural and synthetic compounds, and 3045 ESI-MS(2) data of 679 synthetic drugs contributed by 16 research groups (January 2010). ESI-MS(2) data were analyzed under nonstandardized, independent experimental conditions. MassBank is a distributed database. Each research group provides data from its own MassBank data servers distributed on the Internet. MassBank users can access either all of the MassBank data or a subset of the data by specifying one or more experimental conditions. In a spectral search to retrieve mass spectra similar to a query mass spectrum, the similarity score is calculated by a weighted cosine correlation in which weighting exponents on peak intensity and the mass-to-charge ratio are optimized to the ESI-MS(2) data. MassBank also provides a merged spectrum for each compound prepared by merging the analyzed ESI-MS(2) data on an identical compound under different collision-induced dissociation conditions. Data merging has significantly improved the precision of the identification of a chemical compound by 21-23% at a similarity score of 0.6. Thus, MassBank is useful for the identification of chemical compounds and the publication of experimental data.
1,689 citations
••
TL;DR: The data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.
Abstract: The efficacy and safety of donepezil as a treatment for patients with mild to moderate Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. Patients were randomly assigned to treatment with placebo (n = 162), 5 mg/d donepezil (n = 154), or 10 mg/d donepezil (n = 157) for 24 weeks followed by a 6-week, single-blind placebo washout. The primary efficacy measures were the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) and the Clinician's Interview Based Assessment of Change-Plus (CIBIC plus), with the Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale-Sum of the Boxes (CDR-SB), and patient rated Quality of Life (QoL) used as secondary measures. Cognitive function, as measured by the ADAS-cog, was significantly improved in the 5- and 10-mg/d donepezil groups as compared with the placebo group at weeks 12, 18, and 24. Clinician's global ratings on the CIBIC plus also improved in both the 5- and 10-mg/d donepezil groups relative to placebo. At the end of the 6-week placebo washout phase, ADAS-cog scores and CIBIC plus ratings were not significantly different for the three groups. Significant treatment benefits were also observed consistently in both the 5- and 10-mg/d groups on the MMSE and the CDR-SB, but there was no consistent effect on the patient-rated QoL. Cholinergic side effects (primarily diarrhea, nausea, and vomiting) were reported more often in the 10-mg/d group than either the 5-mg/d or placebo groups. Side effects were transient and generally mild in severity. These data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.
1,519 citations
Authors
Showing all 4445 results
Name | H-index | Papers | Citations |
---|---|---|---|
James Chih-Hsin Yang | 127 | 606 | 90323 |
Yoshimi Takai | 122 | 680 | 61478 |
Harald Hampel | 109 | 601 | 65160 |
Walter Birchmeier | 105 | 255 | 50551 |
Phil S. Baran | 99 | 419 | 31302 |
Yasuo Uchiyama | 97 | 396 | 46807 |
Shigetada Nakanishi | 94 | 253 | 34470 |
James Larkin | 88 | 519 | 66880 |
Tatsuhiro Shibata | 78 | 260 | 25569 |
Takao Koike | 72 | 524 | 27122 |
Wolfgang Weninger | 72 | 325 | 21882 |
Koji Yamada | 71 | 810 | 21893 |
Hans J. Hansen | 69 | 292 | 12267 |
Dinesh Kumar | 69 | 1333 | 24342 |
Satoshi Ogawa | 67 | 314 | 17304 |